5 terminated. 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Terminated 5 |
Follow Advanced Malignant Neoplasm: new trials by email Literature Review of Advanced Malignant Neoplasm trials Research Report on Advanced Malignant Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors. TQB2928 injection, Penpulimab - Advanced Malignant Neoplasm | Phase 1 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 3 | 2024-05-24 | 2024-08-06 |
| A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies AUR106 - Relapse, Advanced Malignant Neoplasm | Phase 1 | Terminated | Aurigene Discovery Technologies Limited | 21 | 2023-08-26 | 2026-04-17 |
| Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer Bevacizumab, Fluorouracil, Leucovorin - Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver | Phase 1 | Terminated | M.D. Anderson Cancer Center | 38 | 2020-06-23 | 2026-07-27 |
| First-in-Human Study of KO-947 in Non-Hematological Malignancies KO-947 - Advanced Malignant Neoplasm | Phase 1 | Terminated | Kura Oncology, Inc. | 61 | 2017-04-06 | 2021-09-20 |
| Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Bevacizumab, Cetuximab, Laboratory Biomarker Analysis - Advanced Malignant Neoplasm, Castleman Disease | Phase 1 | Terminated | M.D. Anderson Cancer Center | 154 | 2012-10-16 | 2026-05-15 |
Carcinoma, Transitional Cell (2) · Neoplasms (2) · Recurrence (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Castleman Disease (1) · Colonic Neoplasms (1) · Endocrine Gland Neoplasms (1) · Erdheim-Chester Disease (1) · Esophageal Neoplasms (1) · Kidney Neoplasms (1) · Lymphangioleiomyomatosis (1) · Mouth Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms, Mesothelial (1)
Carcinoma (2) · Disease Attributes (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Head and Neck Neoplasms (2) · Male Urogenital Diseases (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Urologic Diseases (2) · Breast Diseases (1)
Bevacizumab (2) · Disulfides (2) · Immunoglobulin G (2) · Sirolimus (2) · temsirolimus (2) · Cetuximab (1) · Doxorubicin (1) · Fluorouracil (1) · Leucovorin (1) · Oxaliplatin (1) · Valproic Acid (1) · dehydroftorafur (1) · liposomal doxorubicin (1) · penpulimab (1)
M.D. Anderson Cancer Center (2) · Aurigene Discovery Technologies Limited (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Kura Oncology, Inc. (1)
United States (3) · China (1) · India (1) · Spain (1)
Akhil Kumar, MD (1) · Sarina A Piha-Paul (1) · Siqing Fu (1)
P30CA016672 (1)